CLAIMS

1. Use of a composition comprising nanoparticles comprising a taxane and an albumin in the manufacture of a medicament for the treatment of cancer in an individual; wherein the medicament is to be administered with a hedgehog inhibitor, wherein the hedgehog inhibitor is cyclopamine, IPI926, or IPI609.

2. The use according to claim 1, wherein the medicament is to be administered with an effective amount of gemcitabine.

3. The use according to claim 1 or claim 2, wherein the cancer is selected from the group consisting of basal cell carcinoma, medulloblastoma, glioblastoma, multiple myeloma, chronic myelogenous leukemia (CML), acute myelogenous leukemia, pancreatic cancer, lung cancer (small cell lung cancer and non-small cell lung cancer), esophageal cancer, stomach cancer, biliary cancer, prostate cancer, liver cancer, hepatocellular cancer, gastrointestinal cancer, gastric cancer, ovarian cancer, and bladder cancer.

4. The use according to claim 3, wherein the cancer is pancreatic cancer.

5. The use according to claim 3, wherein the cancer is basal cell carcinoma.

6. The use according to any one of claims 1-5, wherein the composition comprising nanoparticles comprising taxane and albumin and the hedgehog inhibitor are to be administered simultaneously.

7. The use according to any one of claims 1-5, wherein the composition comprising nanoparticles comprising taxane and albumin and the hedgehog inhibitor are to be administered sequentially.

8. The use according to any one of claims 1-7, wherein the taxane is paclitaxel.

~~9. The use according to any one of claims 1-7, wherein the taxane is docetaxel.~~

10. The use according to any one of claims 1-9, wherein the average diameter of the nanoparticles in the composition is no greater than 200 nm.

11. The use according to any one of claims 1-10, wherein the weight ratio of the albumin and the taxane in the nanoparticle composition is less than 1:1 to 9:1.

12. The use according to any one of claims 1-11, wherein the individual is a human.

13. The use according to any one of claims 1-12, wherein the hedgehog inhibitor is to be administered orally.

14. The use according to any one of claims 1-13, wherein the hedgehog inhibitor is to be administered prior to the administration of the nanoparticle composition.

15. The use according to any one of claims 1-13, wherein the hedgehog inhibitor is to be administered after the administration of the nanoparticle composition.

CLAIMS

1. Use of a composition comprising nanoparticles comprising a taxane and an albumin in the manufacture of a medicament for the treatment of cancer in an individual; wherein the medicament is formulated for administration with a hedgehog inhibitor, wherein the hedgehog inhibitor is cyclopamine, IPI926, or IPI609.

2. The use according to claim 1, wherein the medicament is formulated for administration with an effective amount of gemcitabine.

3. The use according to claim 1 or claim 2, wherein the cancer is selected from the group consisting of basal cell carcinoma, medulloblastoma, glioblastoma, multiple myeloma, chronic myelogenous leukemia (CML), acute myelogenous leukemia, pancreatic cancer, lung cancer (small cell lung cancer and non-small cell lung cancer), esophageal cancer, stomach cancer, biliary cancer, prostate cancer, liver cancer, hepatocellular cancer, gastrointestinal cancer, gastric cancer, ovarian cancer, and bladder cancer.

4. The use according to claim 3, wherein the cancer is pancreatic cancer.

5. The use according to claim 3, wherein the cancer is basal cell carcinoma.

6. The use according to any one of claims 1-5, wherein the medicament is formulated for simultaneous administration with the hedgehog inhibitor.

7. The use according to any one of claims 1-5, wherein the medicament is formulated for sequential administration with the hedgehog inhibitor.

8. The use according to any one of claims 1-7, wherein the taxane is paclitaxel.

9. The use according to any one of claims 1-7, wherein the taxane is docetaxel.

10. The use according to any one of claims 1-9, wherein the average diameter of the nanoparticles in the composition is no greater than 200 nm.

11. The use according to any one of claims 1-10, wherein the weight ratio of the albumin and the taxane in the nanoparticle composition is 1:1 to 9:1.

12. The use according to any one of claims 1-11, wherein the individual is a human.

13. The use according to any one of claims 1-12, wherein the hedgehog inhibitor is formulated for oral administration.

14. The use according to any one of claims 1-13, wherein the medicament is formulated for administration following the hedgehog inhibitor.

15. The use according to any one of claims 1-13, wherein the medicament is formulated for administration prior to the hedgehog inhibitor.